Antibiotic resistance and molecular characterization of clinical isolates of methicillin-resistant coagulase-negative staphylococci isolated from bacteremic patients in oncohematology
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- antibakteriální látky farmakologie MeSH
- bakteriální geny MeSH
- bakteriální léková rezistence MeSH
- bakteriemie mikrobiologie MeSH
- DNA bakterií genetika metabolismus MeSH
- hematologické nádory komplikace MeSH
- koagulasa metabolismus MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- molekulární typizace MeSH
- polymerázová řetězová reakce metody MeSH
- pulzní gelová elektroforéza MeSH
- restrikční endonukleasy typu II metabolismus MeSH
- rezistence na methicilin * MeSH
- stafylokokové infekce mikrobiologie MeSH
- Staphylococcus epidermidis klasifikace účinky léků genetika izolace a purifikace MeSH
- Staphylococcus haemolyticus klasifikace účinky léků genetika izolace a purifikace MeSH
- Staphylococcus hominis klasifikace účinky léků genetika izolace a purifikace MeSH
- techniky typizace bakterií MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Tunisko MeSH
- Názvy látek
- antibakteriální látky MeSH
- CCCGGG-specific type II deoxyribonucleases MeSH Prohlížeč
- DNA bakterií MeSH
- koagulasa MeSH
- restrikční endonukleasy typu II MeSH
Polymerase chain reaction (PCR) amplification of antibiotic resistance genes as well as staphylococcal cassette chromosome mec (SCCmec) typing and pulsed-field gel electrophoresis (PFGE) of SmaI macrorestriction fragments of genomic DNA were used to characterize 45 methicillin-resistant coagulase-negative staphylococci (MRCoNS) isolates responsible of bacteremia recovered in patients at the Bone Marrow Transplant Centre of Tunisia in 1998-2007. Among the 45 MRCoNS isolates, Staphylococcus epidermidis was the most prevalent species (75.6%) followed by Staphylococcus haemolyticus (22.2%) and Staphylococcus hominis (2.2%). Extended susceptibility profiles were generated for MRCoNS against 16 antimicrobial agents. Out of 45 mecA-positive strains, 43 (95.6%) were phenotypically methicillin-resistant and two (4.4%) were methicillin-susceptible. The msr(A) was the most prevalent gene (13 isolates; 48.1%) among erythromycin-resistant isolates. The erm(C) was found alone in seven (25.9%) or in combination with both erm(A) and erm(B) in two (7.4%) isolates. The aac(6')-Ie-aph(2″)-Ia was the most prevalent gene among aminoglycoside-resistant isolates, detected alone in 14 isolates (33.3%) isolates, in combination with ant(4')-Ia in 18 (42.8%) isolates, in combination with aph(3')-IIIa in four (9.5%) or with both ant(4')-Ia and aph(3')-IIIa in two (4.7%) isolates. The ant(4')-Ia was detected in three (7.1%) isolates and the aph(3')-IIIa in one (2.4%) isolate. Among tetracycline-resistant isolates, six (85.7%) strains harbored the tet(K) gene and one (14.3%) strain carried tet(K) and tet(M) genes. SCCmec types IV (31%) and III (24.5%), the most prevalent types detected, were found to be more resistant to non-β-lactam antibiotics. A wide diversity of isolates was observed by PFGE among MRCoNS.
Zobrazit více v PubMed
J Clin Microbiol. 2008 Nov;46(11):3778-83 PubMed
FEMS Immunol Med Microbiol. 2003 Sep 22;38(2):153-8 PubMed
BMC Infect Dis. 2007 Apr 18;7:29 PubMed
Antimicrob Agents Chemother. 2009 Dec;53(12):4961-7 PubMed
Antimicrob Agents Chemother. 2004 Jul;48(7):2637-51 PubMed
J Antimicrob Chemother. 2000 Jun;45(6):843-9 PubMed
J Clin Microbiol. 2002 Jul;40(7):2638-41 PubMed
West Indian Med J. 2006 Jun;55(3):170-3 PubMed
J Antimicrob Chemother. 2000 Jun;45(6):763-70 PubMed
Eur J Clin Microbiol Infect Dis. 2000 Oct;19(10):755-8 PubMed
Antimicrob Agents Chemother. 1999 May;43(5):1062-6 PubMed
Antimicrob Agents Chemother. 2007 May;51(5):1671-7 PubMed
Antimicrob Agents Chemother. 2000 Feb;44(2):231-8 PubMed
Antimicrob Agents Chemother. 2003 Dec;47(12):3926-34 PubMed
Curr Pharm Des. 1998 Apr;4(2):155-80 PubMed
J Med Microbiol. 2007 Oct;56(Pt 10):1328-1333 PubMed
Antimicrob Agents Chemother. 2003 Nov;47(11):3574-9 PubMed
Microbiol Rev. 1993 Mar;57(1):138-63 PubMed
Vet Res. 2001 May-Aug;32(3-4):341-62 PubMed
Curr Microbiol. 2008 Nov;57(5):442-8 PubMed
Antimicrob Agents Chemother. 2001 May;45(5):1323-36 PubMed
Antimicrob Agents Chemother. 1999 Jun;43(6):1449-58 PubMed
Antimicrob Agents Chemother. 1990 Nov;34(11):2164-8 PubMed
Blood Rev. 2009 May;23(3):113-22 PubMed
Antimicrob Agents Chemother. 2002 Sep;46(9):3061-4 PubMed
Clin Microbiol Infect. 2007 Aug;13(8):777-81 PubMed
Microb Drug Resist. 2000 Fall;6(3):189-98 PubMed
Indian J Med Microbiol. 2002 Jan-Mar;20(1):45-6 PubMed
J Clin Microbiol. 2002 Nov;40(11):4289-94 PubMed
Clin Microbiol Infect. 2003 Dec;9(12):1179-86 PubMed
J Clin Microbiol. 2008 Jan;46(1):118-29 PubMed
Epidemiol Infect. 2001 Apr;126(2):197-204 PubMed
J Clin Microbiol. 2004 Feb;42(2):542-7 PubMed
Antimicrob Agents Chemother. 2006 Aug;50(8):2782-8 PubMed
J Bacteriol. 2007 Mar;189(6):2540-52 PubMed
J Antimicrob Chemother. 2004 Nov;54(5):889-96 PubMed
Pathol Biol (Paris). 2004 Mar;52(2):82-8 PubMed
Diagn Microbiol Infect Dis. 2008 Aug;61(4):387-95 PubMed
Microbiol Res. 2009;164(4):404-10 PubMed
J Clin Microbiol. 2000 Feb;38(2):877-80 PubMed
Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents PubMed
J Clin Microbiol. 2005 Oct;43(10):5026-33 PubMed
J Clin Microbiol. 1995 Sep;33(9):2233-9 PubMed
Microb Drug Resist. 2000 Fall;6(3):199-211 PubMed
J Bacteriol. 2001 Apr;183(8):2417-24 PubMed
